<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760288</url>
  </required_header>
  <id_info>
    <org_study_id>CO42865</org_study_id>
    <secondary_id>2020-005269-15</secondary_id>
    <nct_id>NCT04760288</nct_id>
  </id_info>
  <brief_title>A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).</brief_title>
  <acronym>AcceleRET-MTC</acronym>
  <official_title>A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the efficacy and safety of pralsetinib compared with SOC treatment&#xD;
      (cabozantinib or vandetanib) for participants with RET (rearranged during&#xD;
      transfection)-mutant MTC who have not previously received a SOC MultiKinase Inhibitor (MKI)&#xD;
      therapy. Participants will be randomized in a 1:1 ratio into one of two treatment arms: Arm A&#xD;
      (pralsetinib) or Arm B (investigator's choice of either cabozantinib or vandetanib).&#xD;
      Participants whose disease progresses during SOC treatment will be offered the option to&#xD;
      cross over to receive pralsetinib after confirmation of progressive disease by blinded&#xD;
      independent central review (BICR).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 9, 2022</start_date>
  <completion_date type="Anticipated">April 15, 2028</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 11 years</time_frame>
    <description>Defined as the time from randomisation date to the first documented PD (Progression of Disease), as assessed by BICR according to RECIST v1.1 or death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-To-Treatment Failure (TTF)</measure>
    <time_frame>Up to 13 years</time_frame>
    <description>Defined as the time from randomisation date to the discontinuation of study drug during the treatment period due to death, treatment-related adverse event, or PD, as assessed by BICR according to RECIST v1.1, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 13 years</time_frame>
    <description>Defined as the proportion of participants who achieve a CR (Complete Response) or a PR (Partial Response) prior to progressive disease and/or other anti-cancer therapy, as assessed by BICR according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 13 years</time_frame>
    <description>Defined as the time from randomisation date to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>Up to 13 years</time_frame>
    <description>Incidence and severity determined according to the NCI CTCAE v5.0 (National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 13 years</time_frame>
    <description>Defined as the number of weeks from the time criteria are first met for either a CR or a PR, until the date of documented PD, as assessed by BICR according to RECIST v1.1, or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 13 years</time_frame>
    <description>Defined as the proportion of participants who experience a best response of CR, PR, or stable disease, as assessed by BICR according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Up to 13 years</time_frame>
    <description>Defined as the proportion of patients who experience a CR or a PR or a best response of stable disease with a minimum duration of 6 months, as assessed by BICR according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration of function</measure>
    <time_frame>Up to 13 years</time_frame>
    <description>Defined as the time from randomization to the date of a participant's first &gt;= 10-point decrease from baseline score, as assessed through the use of the EORTC QLQ-C30 Physical Function scale, Role Function and Pain scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>Up to 13 years</time_frame>
    <description>Defined as the time from randomization to the date of a participant's first &gt;= 10-point decrease from baseline score, as assessed through the use of the GHS (Global Health Status)/QoL scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability and Palatability of Pralsetinib capsules</measure>
    <time_frame>Up to 13 years</time_frame>
    <description>Acceptability Survey scores on Day 1 of Cycle 1 and Crossover Cycle 1 (each cycle is 28 days).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (Pralsetinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Pralsetinib at a dose of 400mg orally once daily (PO QD) in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (SOC: Cabozantinib/Vandetanib)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive either one of the following SOC therapies, as determined by the treating investigator: Cabozantinib: 140mg PO QD in 28-day cycles; Vandetanib: 300mg PO QD in 28-day cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pralsetinib</intervention_name>
    <description>Participants will receive Pralsetinib at a dose of 400mg, as per the dosing schedule described above.</description>
    <arm_group_label>Arm A (Pralsetinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Participants will receive Cabozantinib at a dose of 140mg, as per the dosing schedule described above.</description>
    <arm_group_label>Arm B (SOC: Cabozantinib/Vandetanib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib</intervention_name>
    <description>Participants will receive Vandetanib at a dose of 300mg, as per the dosing schedule described above.</description>
    <arm_group_label>Arm B (SOC: Cabozantinib/Vandetanib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have histologically confirmed unresectable locally advanced or metastatic MTC and&#xD;
             be a candidate for systemic therapy with SOC MKI.&#xD;
&#xD;
          -  Must have received no prior systemic anticancer treatment with MKI therapies for&#xD;
             advanced or metastatic MTC.&#xD;
&#xD;
          -  Must have radiologically confirmed progressive disease within the last 14 months and&#xD;
             at least one of the following: [1] A MTC-associated symptom and [2] CLN (Calcitonin)&#xD;
             and CEA (carcinoembryonic antigen) level doubling time of less than 24 months.&#xD;
&#xD;
          -  Confirmed RET mutation.&#xD;
&#xD;
          -  Must be able to swallow an oral medication.&#xD;
&#xD;
          -  Must have an ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2.&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use appropriate contraception during the treatment period&#xD;
             and for the respective period of time after final dose of study drug.&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             appropriate contraception during the treatment period and for the respective period of&#xD;
             time after final dose of study drug and to refrain from donating sperm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who are pregnant or breastfeeding, or intending to become pregnant during&#xD;
             the study within 14 days after the final dose of pralsetinib or within 4 months after&#xD;
             the final dose of vandetanib or cabozantinib.&#xD;
&#xD;
          -  Have disease that is suitable for surgery or radiotherapy administered with curative&#xD;
             intent.&#xD;
&#xD;
          -  Have been previously treated with any systemic kinase inhibitor therapy regimens,&#xD;
             including a selective RET inhibitor, given for recurrent and/or metastatic disease.&#xD;
&#xD;
          -  Have received any radiation therapy within 14 days prior to Day 1 of Cycle 1 and any&#xD;
             related toxicity must be resolved to Grade 1 or better.&#xD;
&#xD;
          -  Participant's tumor has any additional known primary driver alterations other than&#xD;
             RET.&#xD;
&#xD;
          -  Have known hypersensitivity to pralsetinib, vandetanib, or cabozantinib, or any of&#xD;
             their ingredients.&#xD;
&#xD;
          -  Have a history of pneumonitis within the last 12 months.&#xD;
&#xD;
          -  Have ongoing treatment with chronic immunosuppressants or systemic steroids &gt;10&#xD;
             mg/day.&#xD;
&#xD;
          -  Have any history of hereditary bleeding disorder or any evidence of hematemesis.&#xD;
&#xD;
          -  Have had major surgery or invasive dental procedure within 3 weeks prior to Day 1 of&#xD;
             Cycle 1.&#xD;
&#xD;
          -  Have CNS metastases that are associated with progressive neurologic symptoms,&#xD;
             untreated spinal cord compression or requires increasing doses of corticosteroids to&#xD;
             control the CNS disease.&#xD;
&#xD;
          -  Have clinically significant, uncontrolled, cardiovascular disease.&#xD;
&#xD;
          -  Have required treatment with a prohibited medication or herbal remedy.&#xD;
&#xD;
          -  Have received hematopoietic growth factor support or transfusion within 14 days of the&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  Had a major surgical procedure within 14 days of the first dose of study drug.&#xD;
&#xD;
          -  Have a history of another primary malignancy that has been diagnosed or required&#xD;
             therapy within the past 2 years before randomisation.&#xD;
&#xD;
          -  Have a serious infection requiring intravenous (IV) antibiotics within 7 days prior to&#xD;
             initiation of study treatment.&#xD;
&#xD;
          -  Have an active, uncontrolled infection (viral, bacterial, or fungal) or is positive&#xD;
             for Hepatitis B/C infections (HBV/HCV) or HIV.&#xD;
&#xD;
          -  Have received organ or allogenic bone marrow or peripheral blood stem cell transplant.&#xD;
&#xD;
          -  Is a female who is unwilling to abstain from sexual intercourse or employ highly&#xD;
             effective contraception from the time of informed consent and for at least 4 months&#xD;
             after the last dose of study drug.&#xD;
&#xD;
          -  Is a male who is unwilling to abstain from sexual intercourse or employ highly&#xD;
             effective contraception from the time of informed consent and for at least 120 days&#xD;
             after the final dose of study drug.&#xD;
&#xD;
          -  Have prior or ongoing clinically significant illness, medical condition, surgical&#xD;
             history, physical finding, or laboratory abnormality that, in the Investigator's or&#xD;
             Sponsor's opinion, could affect the safety of the patient or impair the assessment of&#xD;
             study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: CO42865 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Metabolicas (Idim)</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Privado CEMAIC</name>
      <address>
        <city>Córdoba</city>
        <zip>5008</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico de la Fundacion Estudios Clinicos</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Britanico de Rosario</name>
      <address>
        <city>Rosario</city>
        <zip>S2000CVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación Clínica - Clínica Viedma</name>
      <address>
        <city>Viedma</city>
        <zip>R8500ACE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macquarie University Hospital</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Center Research</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital;Clinical Trial Pharmacy</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz; Klinische Abteilung für Allgemeine HNO</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CETUS Hospital Dia Oncologia</name>
      <address>
        <city>Uberaba</city>
        <state>MG</state>
        <zip>38082-049</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre (HCPA) - PPDS</name>
      <address>
        <city>Porto Alegre</city>
        <state>PA</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade Da Santa Casa de Misericordia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90050-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Pio XII Hospital de Câncer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01246 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Uni Hospital; Department of medicinal oncology</name>
      <address>
        <city>Panagyurishte</city>
        <zip>4500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center Plovdiv; Department of Medical Oncology and Oncology Diseases in Pneumology</name>
      <address>
        <city>Plovdiv</city>
        <zip>4004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital For Active Treatment &quot;Sveti Ivan Rilski&quot; EAD; clinical hematology</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre; Dept of Pathology</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute; Clinical Trials</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center; Glen-Cedars Cancer Centre, Oncology Pharmacy</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke; Pharmacie de Chimiotherapie</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Osijek; Hematology</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Sestre Milosrdnice</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital, Onkologisk Afdeling, Klinisk Forsknings Enhed</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu -Angers; Pharmacie / Secteur Essais Cliniques</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EDOG - Institut Bergonie - PPDS</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Lyon; Institut Hématologique et d'Oncologie Pédiatrique</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne Centre Régional de Lutte Contre Le Cancer</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie; Pharmacie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICANS</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cancer de Toulouse Oncopole; IUCT- Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Attikon University General Hospital</name>
      <address>
        <city>Ahens</city>
        <zip>124 64</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Athens Medical School - Regional General Hospital Alexandra</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kianous Stavros</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem, II. Belgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panchshil Hospital</name>
      <address>
        <city>Ahmadabad CITY</city>
        <state>Gujarat</state>
        <zip>380005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unity Hospital-Surat</name>
      <address>
        <city>Surat CITY</city>
        <state>Gujarat</state>
        <zip>395010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital; Dept of Medical Oncology</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCG NCHRI Cancer Center</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital &amp; Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sparsh Hospitals &amp; Critical Care (P) Ltd.</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Odisha</state>
        <zip>751007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayanand Medical College and Hospital</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Regional Reina Sofia - PPDS</name>
      <address>
        <city>Cordoba</city>
        <state>Calabria</state>
        <zip>14004</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center - PPDS</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Hospital of Sacred Heart</name>
      <address>
        <city>Baguio City</city>
        <zip>2600</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center - Quezon City</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut Im. Marii Skłodowskiej Curie; I Klinika Radioterapii i Chemioterapii</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie w Krakowie - Apteka/Pharmacy; Pharmacy</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.</name>
      <address>
        <city>Lisbon</city>
        <zip>1050-034</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Endocrinologie &quot;C. I. Parhon&quot;; Sectorul 1 BUCUREȘTI</name>
      <address>
        <city>Bucuresti</city>
        <zip>011852</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof Dr I Chiricuta Institute of Oncology; Oncology Department</name>
      <address>
        <city>Cluj-napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onco Clinic Consult SA</name>
      <address>
        <city>Craiova</city>
        <zip>200094</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS - H. Clinico U. de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>LA Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra; Servicio de Farmacia</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Madrid - España; Servicio de Farmacia</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro - CIOCC; Farmacia - Ensayos Clínicos</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Malaga</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital, Mahidol Uni ; Division of Rheumatology, Dept. of Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University Hospital; Hematology</name>
      <address>
        <city>Pathum Wan</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI Institute for general and urgent surgery n.a. V.T.Zaitseva of NAMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkiv Governorate</state>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise &quot;City Clinical Hospital # 4&quot; of Dnipro City Council - PPDS</name>
      <address>
        <city>Dnipro</city>
        <state>KIEV Governorate</state>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ukr. Scientific Practical Center of Endocrine Surgery,Transplantation of Endocrine organs&amp;Tissues</name>
      <address>
        <city>Kyiv</city>
        <state>KIEV Governorate</state>
        <zip>01021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Verum Expert LLC</name>
      <address>
        <city>Kyiv</city>
        <state>KIEV Governorate</state>
        <zip>03039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima</name>
      <address>
        <city>Kyiv</city>
        <state>KIEV Governorate</state>
        <zip>03126</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guys Hospital; Guys Cancer Center</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pralsetinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

